Oncology Peer Review On-The-Go: Improving Testing Access and Guiding Treatment Options with TrialJectory

Podcast

The latest podcast episode of Oncology Peer Review On-The-Go features a conversation with Tzvia Bader and Karine Perreault on TrialJectory’s platform, which seeks to guide patients with cancer on their treatment journey.

This week’s conversation focuses on TrialJectory, a digital health company that utilizes artificial intelligence to help guide patients with cancer on their treatment journey. CancerNetwork spoke with Tzvia Bader, chief executive officer and co-founder of TrialJectory, and Karine Perreault, who recently was diagnosed with breast cancer and is on the TrialJectory platform.

The conversation touches on the perceived disconnect between the pharmaceutical industry and patients, the need to remove barriers to access testing, and the action items they think need to be prioritized in order to improve access for women with cancer.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Related Content